Tango Therapeutics, Inc.
TNGXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. With a market capitalization of $3.80B, it sits in mid-cap territory. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Market Cap
$3.80B
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
-13.51
EPS (TTM)
$-0.84
EPS (Fwd)
$-1.67
ROE
-21.3%
ROA
-13.0%
Cash
$1.01B
Total Debt
$32.0M
Free CF
-$71.9M
52W Change
230.2%
Annual Financials
Cash vs Debt
Where TNGX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TNGX finished 1.28% below its 150-day moving average ($22.61) and 14.76% above its 200-day moving average ($19.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TNGX overbought or oversold?
At the September 3, 2026 close, TNGX's RSI(14) was 27.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Tango Therapeutics, Inc. holds $1.01B in cash against $32.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$71.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -21.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $24.9M (2022) to $62.4M (2025), reflecting a 151% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TNGX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.